



Practitioner's Docket No. MPI00-212CP1CN1RCEM

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:	Coyle, Anthony J. et al.		
Application No.:	10/644,671	Group No.:	1644
Filed:	August 20, 2003	Examiner:	Ouspenski, Ilia I.
For:	SCREENING METHODS USING B7-H2 MOLECULES, MEMBERS OF THE B7 FAMILY (as amended)		

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**AMENDMENT AND RESPONSE**

Sir: In response to the Office action mailed February 28, 2007, entry and consideration of the following remarks and amendments is requested:

**Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this paper.

**Remarks/Arguments** begin on page 4 of this paper.

08/16/2007 CCHAU1 00000070 501668 10644671  
02 FC:1253 1020.00 DA

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

- ☒ deposited with the United States Postal Service in an envelope addressed to the Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**37 C.F.R. SECTION 1.8(a)**

**37 C.F.R. SECTION 1.10\***

- ☐ with sufficient postage as first class mail.

- ☒ as "Express Mail Post Office to Addressee"  
Mailing Label No. EV475151977US

**TRANSMISSION**

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Sean Hunziker/Beverly Sotgiopoulos

(type or print name of person certifying)

Date: August 15, 2007

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

27. (Previously Presented) The method of claim 24, wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of:

- a) direct detection of test compound/polypeptide binding;
- b) a competition binding assay; and
- c) a two-hybrid assay or three-hybrid assay.

28. (Previously Presented) The method of claim 24, wherein the test compound is labeled.

29. (Previously Presented) The method of claim 28, wherein the label is selected from the group consisting of a radioisotope label and an enzymatic label.

30. (Previously Presented) The method of claim 24, wherein the polypeptide is a fusion protein further comprising heterologous sequences.

31. (Previously Presented) The method of claim 26, wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of:

- a) cytokine production assay; and
- b) T-cell proliferation assay.

32. (Previously Presented) The method of claim 24, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:4.

33. (Previously Presented) The method of claim 24, wherein the polypeptide is encoded by the nucleotide sequence set forth in SEQ ID NO:3 or SEQ ID NO:21.